Antivirals: Difference between revisions
(Text replacement - "OR" to "'''OR'''") |
(Updated links) |
||
| Line 25: | Line 25: | ||
**[[Emtricitabine/tenofovir]] (Truvada) + raltegravir | **[[Emtricitabine/tenofovir]] (Truvada) + raltegravir | ||
**[[Emtricitabine/tenofovir]] + dolutegravir | **[[Emtricitabine/tenofovir]] + dolutegravir | ||
**Abacavir/lamivudine (Epzicom) + dolutegravir '''OR''' abacavir/lamivudine/dolutegravir (Triumeq) | **[[Abacavir/lamivudine]] (Epzicom) + dolutegravir '''OR''' [[abacavir/lamivudine]]/dolutegravir (Triumeq) | ||
**[[Emtricitabine/tenofovir]]/elvitegravir/cobicistat (Stribild) | **[[Emtricitabine/tenofovir]]/elvitegravir/cobicistat (Stribild) | ||
**[[Emtricitabine/tenofovir]] + ritonavir + darunavir | **[[Emtricitabine/tenofovir]] + ritonavir + darunavir | ||
Revision as of 23:33, 17 June 2018
Anti-herpetic agents
Anti-influenza agents
Adamantane Derivatives
Neuraminidase Inhibitors
Interferons
HAART
- HIV regimen that typically consists of combination of 2 nucleoside and/or non-nucleoside reverse transcriptase inhibitors PLUS a protease inhibitor, reverse-transcriptase inhibitor, or integrase inhibitor
- US DHHS first-line regimens
- Emtricitabine/tenofovir (Truvada) + raltegravir
- Emtricitabine/tenofovir + dolutegravir
- Abacavir/lamivudine (Epzicom) + dolutegravir OR abacavir/lamivudine/dolutegravir (Triumeq)
- Emtricitabine/tenofovir/elvitegravir/cobicistat (Stribild)
- Emtricitabine/tenofovir + ritonavir + darunavir
- WHO first-line regimen
- Emtricitabine/tenofovir/efavirenz (Atripla)
- Tenofovir + lamivudine + efavirenz